Dynavax Technologies (NASDAQ:DVAX) Reaches New 1-Year High – Here’s What Happened

Dynavax Technologies Corporation (NASDAQ:DVAX) shares hit a new 52-week high on Monday . The stock traded as high as $15.71 and last traded at $15.6950, with a volume of 2115139 shares trading hands. The stock had previously closed at $15.41.

Analyst Ratings Changes

Several analysts have recently commented on DVAX shares. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. William Blair lowered Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Stock Up 1.8%

The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The business’s fifty day moving average price is $12.12 and its two-hundred day moving average price is $10.96. The stock has a market capitalization of $1.84 billion, a PE ratio of -42.42 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The company had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. On average, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insider Activity at Dynavax Technologies

In related news, COO David F. Novack sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $15.49, for a total value of $464,700.00. Following the sale, the chief operating officer owned 111,451 shares in the company, valued at $1,726,375.99. This represents a 21.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.98% of the stock is owned by company insiders.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Hantz Financial Services Inc. increased its stake in shares of Dynavax Technologies by 236.9% in the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares during the period. LSV Asset Management acquired a new stake in Dynavax Technologies during the 3rd quarter worth about $89,000. Osaic Holdings Inc. raised its stake in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares during the last quarter. Callan Family Office LLC acquired a new position in Dynavax Technologies in the second quarter valued at approximately $107,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at $109,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.